TrivarX Limited (AU:TRI) has released an update.
TrivarX Limited is advancing to the final stages of clinical trials for its AI-driven MEB-001 algorithm, aimed at improving the screening of Major Depressive Episodes (cMDE) after successful Phase 2 studies. The company is coordinating with the FDA to finalize the pivotal trial protocol, with the trial set to begin following the next quarter’s pre-submission meeting. This move could potentially lead to FDA approval and commercialization of MEB-001, with strong interest already shown by major US sleep centers.
For further insights into AU:TRI stock, check out TipRanks’ Stock Analysis page.
